;
Skip to main content
Home > SciBX > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Tapping TOPK

    OncoTherapy Science has a potent TOPK inhibitor in a liposomal formulation that avoids the toxicity of other cytokinesis-targeted compounds.

    Published on 11/20/2014
  • Table 1: Adjuvant discovery contracts

    Cover Story: Boosting adjuvants Table 1. Adjuvant discovery contracts. The NIH has awarded contracts totaling more than $70 million for 7 new adjuvant discovery projects. Amounts shown represent the potential …

    Published on 11/13/2014
  • Table 2: Selected adjuvants and adjuvanted vaccines for infectious disease

    Cover Story: Boosting adjuvants Table 2. Selected adjuvants and adjuvanted vaccines for infectious disease. Although many marketed vaccines for infectious diseases use alum as an adjuvant, there are three marketed …

    Published on 11/13/2014
  • Boosting adjuvants

    The NIH is committing $70 million to creating new adjuvants that can work with different types of vaccines and wants industry to get involved.

    Published on 11/13/2014
  • A conversation with Elias Zerhouni

    Sanofi's Elias Zerhouni wants a dedicated national fund to keep young scientists involved in research, which he thinks should be the top policy priority for advancing biomedical innovation.

    Published on 11/6/2014
  • Redistributing BRD4 in inflammation

    A new link between inflammation and atherosclerosis centers on the BET bromodomain protein BRD4 and could provide new targets for intervention.

    Published on 10/30/2014
  • Figure 1: Molecular mechanism of BRD4-regulated inflammation

    Cover Story: Redistributing BRD4 in inflammation Figure 1. Molecular mechanism of BRD4-regulated inflammation. As reported in Brown et al., inflammatory stimuli induce rapid genomewide redistribution of bromodomain …

    Published on 10/30/2014
  • Diagnosing resistance

    The frontier for combating antibiotic resistance is now in developing fast, sensitive and versatile diagnostics that can improve treatment and optimize clinical trials.

    Published on 10/23/2014
  • Figure 1: Venture financing for therapies and diagnostics for bacterial infections

    Cover Story: Diagnosing resistance Figure 1. Venture financing for therapies and diagnostics for bacterial infections. (I) Total amount of venture financing for newly formed companies developing therapies or …

    Published on 10/23/2014
  • Table 1: Selected diagnostic tests in development for bacterial infections

    Cover Story: Diagnosing resistance Table 1. Selected diagnostic tests in development for bacterial infections. Diagnostics are listed from most to least advanced stage of development. Source: BCIQ: BioCentury Online…

    Published on 10/23/2014
  • DisABLing imatinib

    Upregulation of PKC eta has been found to underlie some forms of imatinib resistance in CML, and the discovery could provide new targets for intervention.

    Published on 10/16/2014
  • Figure 1: Circumventing BCR-ABL-independent resistance in CML

    DisABLing imatinib Figure 1. Circumventing BCR-ABL-independent resistance in CML. Resistance to the chronic myelogenous leukemia (CML) drug Gleevec imatinib is often caused by mutations in BCR-ABL tyrosine kinase, …

    Published on 10/16/2014
  • Invigorating IVIG

    arGEN-X is adding to a wave of innovation in IVIG therapy with an engineered recombinant IgG that cleared unwanted antibodies in nonhuman primates 30 times more efficiently than standard IVIG.

    Published on 10/9/2014
  • Table 1: Ig therapies

    Cover Story: Invigorating IVIG Table 1. Ig therapies. At least nine blood-derived Ig products are marketed or approved and at least four next-generation products are in development. Source: BCIQ: BioCentury Online …

    Published on 10/9/2014
  • NAMPT neuroprotection

    Google-backed antiaging play Calico has filled its first pipeline program by in-licensing analogs of P7C3 after new research showed that the molecules block neurodegeneration by inhibiting NAMPT.

    Published on 10/2/2014
  • Interrupting Ebola

    Although different companies are pursuing antibodies, vaccines or siRNAs to fight Ebola, many researchers believe it is not a race between them but a combination of approaches that will win the day.

    Published on 9/25/2014
  • Table 1: Filovirus pipeline

    Cover Story: Interrupting Ebola Table 1. Filovirus pipeline. At least 16 products for filovirus are in development by public and private companies. Gray indicates therapies highlighted in the story. Source: BCIQ: …

    Published on 9/25/2014
  • Neutralizing HIV rebound

    Rockefeller University researchers have shown that broadly neutralizing antibodies against HIV envelope proteins can knock the virus out of its latent reservoirs, thus opening an inroad to fully eliminating HIV from …

    Published on 9/18/2014
  • Kinase convergence on eIF4F

    Researchers in France have shown that the eIF4F complex is a hub in which resistance pathways for BRAF and MEK converge and suggest that combining eIF4F inhibitors with marketed melanoma drugs could circumvent …

    Published on 9/11/2014
  • Box 1: eIF4A profiled

    Cover Story: Kinase convergence on eIF4F Box 1. eIF4A profiled. A team at the Memorial Sloan-Kettering Cancer Center has published data in Nature showing that inhibition of the RNA helicase eukaryotic translation …

    Published on 9/11/2014
  • Selectively splicing SMN2

    A three-way collaboration between PTC, Roche and the Spinal Muscular Atrophy Foundation has resulted in orally available, blood brain barrier-penetrant, selective small molecule modulators of SMN2 that are advancing in …

    Published on 9/4/2014
  • Figure 1: Modulating SMN2 splicing

    Cover Story: Selectively splicing SMN2 Figure 1. Modulating SMN2 splicing. Spinal muscular atrophy (SMA) is caused by insufficient expression of functional and stable survival of motor neuron (SMN) protein, leading …

    Published on 9/4/2014
  • Overcoming ibrutinib resistance

    The CDK4 inhibitor palbociclib might help overcome ibrutinib resistance in mantle cell lymphoma by restoring sensitivity to inhibitors of BTK or PI3K.

    Published on 8/28/2014
  • Figure 1: Blocking signaling to overcome Imbruvica resistance in MCL cells

    Cover Story: Overcoming ibrutinib resistance Figure 1. Blocking signaling to overcome Imbruvica resistance in MCL cells. [a] B cell receptor (BCR) stimulation by an extracellular antigen induces Bruton's tyrosine …

    Published on 8/28/2014
  • Table 1: CDK4 and CDK6 or BTK inhibitors in development for cancer

    Cover Story: Overcoming ibrutinib resistance Table 1. CDK4 and CDK6 or BTK inhibitors in development for cancer. At least five cyclin dependent kinase 4 (CDK4) and CDK6 inhibitors and five Bruton's tyrosine kinase (…

    Published on 8/28/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993